United States Biotechnology & Medical Research

Aprea Therapeutics Inc (APRE)

Track

Aprea Therapeutics Inc. has seen no insider trading activity in the last 90 days. The most recent transactions occurred on January 30, 2026, when CEO Gilad Oren and CFO John P. Hamill both executed buy orders. Prior to this, additional buying activity was recorded in December 2025 by company insiders.
Ticker: APRE Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Aprea Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 30 Jan 2026
Value US$4,597,740.58 | Price 430.12 | Shares 34,073 (-47.8%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-02 2026-01-30 B Purchase
2.6
Hamill John P.

SrVP/CFO/Prin Fin & Acct Ofcr

Officer
34,073 -47.8%
430.12
US$4,597,741 		34,073 -47.8% 430.12 US$4,597,741
2026-02-02 2026-01-30 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
79,843 +19.5%
477.45
US$318,037 		79,843 +19.5% 477.45 US$318,037
2025-12-11 2025-12-10 B Purchase
1.8
Duey Marc
Non-Executive Director
65,859 +21.4%
366.34
US$401,203 		65,859 +21.4% 366.34 US$401,203
2025-12-11 2025-12-10 B Purchase
2.6
Hamill John P.

SrVP/CFO/Prin Fin & Acct Ofcr

Officer
5,000 +22.0%
1.17
US$5,825 		5,000 +22.0% 1.17 US$5,825
2025-04-04 2025-04-03 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
2,497 +0.7%
1.80
US$4,495 		2,497 +0.7% 1.80 US$4,495
2025-04-04 2025-04-03 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
3,003 +0.9%
1.87
US$5,616 		3,003 +0.9% 1.87 US$5,616
2024-10-24 2024-10-23 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
500 +0.2%
3.92
US$1,958 		500 +0.2% 3.92 US$1,958
2024-10-25 2024-10-18 S Sale
1.8
Duey Marc
Non-Executive Director
6,462 -2.7%
4.58
US$29,583 		6,462 -2.7% 4.58 US$29,583
2024-10-17 2024-10-16 B Purchase
1.8
Duey Marc
Non-Executive Director
30,000 +14.3%
4.39
US$131,700 		30,000 +14.3% 4.39 US$131,700
2024-10-16 2024-10-15 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
250 +0.1%
2.90
US$725 		250 +0.1% 2.90 US$725
2024-10-16 2024-10-14 B Purchase
1.8
Duey Marc
Non-Executive Director
190 +0.1%
2.58
US$490 		190 +0.1% 2.58 US$490
2024-10-15 2024-10-14 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
1,000 +0.3%
2.59
US$2,590 		1,000 +0.3% 2.59 US$2,590
2024-10-16 2024-10-11 B Purchase
2.6
Hamill John P.

SrVP/CFO/Prin Fin & Acct Ofcr

Officer
50 +0.3%
2.46
US$123 		50 +0.3% 2.46 US$123
2024-10-15 2024-10-11 B Purchase
2.9
Seizinger Bernd R.
Non-Executive Director
10,000 +28.8%
2.68
US$26,800 		10,000 +28.8% 2.68 US$26,800
2024-10-15 2024-10-10 B Purchase
2.2
Gilad Oren

President/CEO

Executive Director
150 +0.0%
2.54
US$381 		150 +0.0% 2.54 US$381
2024-10-15 2024-10-10 B Purchase
2.6
Hamill John P.

SrVP/CFO/Prin Fin & Acct Ofcr

Officer
450 +2.4%
2.61
US$1,174 		450 +2.4% 2.61 US$1,174
2024-03-14 2024-03-13 B Purchase
2.6
Hamill John P.

SrVP/CFO/Prin Fin & Acct Ofcr

Officer
1,010 +7.0%
7.29
US$7,363 		1,010 +7.0% 7.29 US$7,363
2024-03-14 2024-03-13 B Purchase
2.9
Seizinger Bernd R.
Non-Executive Director
6,860 +25.6%
7.29
US$50,009 		6,860 +25.6% 7.29 US$50,009
2024-03-14 2024-03-13 B Purchase
3.4
HENNEMAN JOHN B III
Non-Executive Director
6,860 +536.4%
7.29
US$50,009 		6,860 +536.4% 7.29 US$50,009
2024-03-14 2024-03-13 B Purchase
2.2
Gilad Oren

President, CEO

Executive Director
2,000 +0.6%
7.29
US$14,580 		2,000 +0.6% 7.29 US$14,580
2023-06-08 2023-06-07 B Purchase
2.9
Seizinger Bernd R.
Non-Executive Director
6,029 +29.7%
3.68
US$22,192 		6,029 +29.7% 3.68 US$22,192
2023-06-08 2023-06-06 B Purchase
2.9
Seizinger Bernd R.
Non-Executive Director
4,068 +25.1%
3.63
US$14,764 		4,068 +25.1% 3.63 US$14,764
2022-05-19 2022-05-18 B Purchase
2.9
Seizinger Bernd R.
Non-Executive Director
50,000 +18.6%
0.71
US$35,500 		50,000 +18.6% 0.71 US$35,500
2022-05-19 2022-05-18 B Purchase
2.2
SCHADE CHRISTIAN S

Chairman & CEO

Executive Director
37,500 +14.7%
0.64
US$24,124 		37,500 +14.7% 0.64 US$24,124
2022-03-01 2022-02-28 PlS Planned sale
Attar Eyal C.

SVP, Chief Medical Officer

Officer
36,000 -43.4%
1.73
US$62,280 		36,000 -43.4% 1.73 US$62,280
2021-12-03 2021-12-01 PlS Planned sale
Korbel Gregory Alan

SVP, Chief Business Officer

Officer
27,500 -61.6%
3.96
US$108,900 		27,500 -61.6% 3.96 US$108,900
2021-11-03 2021-11-01 PlS Planned sale
Korbel Gregory Alan

SVP, Chief Business Officer

Officer
27,500 -61.6%
5.00
US$137,500 		27,500 -61.6% 5.00 US$137,500
2021-10-05 2021-10-01 PlS Planned sale
Korbel Gregory Alan

SVP, Chief Business Officer

Officer
27,500 -61.6%
4.89
US$134,475 		27,500 -61.6% 4.89 US$134,475
2021-10-05 2021-10-01 PlS Planned sale
Abrahmsen Lars B.

SVP, Chief Scientific Officer

Officer
50,000 -72.5%
4.89
US$244,500 		50,000 -72.5% 4.89 US$244,500
2021-02-16 2020-12-28 S Sale
3.2
Redmile Group, LLC
Large shareholder
5,863 -0.3%
5.80
US$34,005 		5,863 -0.3% 5.80 US$34,005
2021-02-16 2020-12-28 S Sale
3.2
Redmile Group, LLC
Large shareholder
494,137 -21.8%
5.58
US$2,757,284 		494,137 -21.8% 5.58 US$2,757,284
2020-10-07 2020-10-05 S Sale
3.6
5AM Ventures IV, L.P.

Former 10% holder
175,000 -55.8%
25.30
US$4,427,500 		175,000 -55.8% 25.30 US$4,427,500
2020-07-07 2020-07-07 S Sale
3.2
KDev Investments AB
Large shareholder
241,703 -10.8%
34.55
US$8,350,839 		241,703 -10.8% 34.55 US$8,350,839
2020-06-18 2020-06-16 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
19,836 -6.0%
33.30
US$660,539 		19,836 -6.0% 33.30 US$660,539
2020-06-18 2020-06-16 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
4,807 -6.0%
33.30
US$160,073 		4,807 -6.0% 33.30 US$160,073
2020-06-18 2020-06-16 S Sale
3.1
ROCKLAGE SCOTT M
Non-Executive Director Large shareholder
4,807 -6.0%
33.30
US$160,073 		4,807 -6.0% 33.30 US$160,073
2020-06-18 2020-06-16 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
115,357 -6.0%
33.30
US$3,841,388 		115,357 -6.0% 33.30 US$3,841,388
2020-06-18 2020-06-16 S Sale
3.1
ROCKLAGE SCOTT M
Non-Executive Director Large shareholder
115,357 -6.0%
33.30
US$3,841,388 		115,357 -6.0% 33.30 US$3,841,388
2020-06-15 2020-06-11 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
9,800 -10.8%
28.75
US$281,776 		9,800 -10.8% 28.75 US$281,776
2020-06-15 2020-06-11 S Sale
3.1
ROCKLAGE SCOTT M
Non-Executive Director Large shareholder
9,800 -10.8%
28.75
US$281,776 		9,800 -10.8% 28.75 US$281,776
2020-06-15 2020-06-11 S Sale
3.1
ROCKLAGE SCOTT M
Non-Executive Director Large shareholder
235,200 -10.8%
28.75
US$6,762,635 		235,200 -10.8% 28.75 US$6,762,635
2020-06-15 2020-06-11 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
235,200 -10.8%
28.75
US$6,762,635 		235,200 -10.8% 28.75 US$6,762,635
2020-05-21 2020-05-19 S Sale
3.1
ROCKLAGE SCOTT M
Non-Executive Director
10,200 -10.1%
35.15
US$358,530 		10,200 -10.1% 35.15 US$358,530
2020-05-21 2020-05-19 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
10,200 -10.1%
35.15
US$358,530 		10,200 -10.1% 35.15 US$358,530
2020-05-21 2020-05-19 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
244,800 -10.1%
35.15
US$8,604,720 		244,800 -10.1% 35.15 US$8,604,720
2020-05-21 2020-05-19 S Sale
3.1
ROCKLAGE SCOTT M
Non-Executive Director
244,800 -10.1%
35.15
US$8,604,720 		244,800 -10.1% 35.15 US$8,604,720
2020-04-15 2020-04-13 S Sale
3.2
KDev Investments AB
Large shareholder
210,548 -8.6%
31.25
US$6,579,625 		210,548 -8.6% 31.25 US$6,579,625
2019-10-09 2019-10-07 B Purchase
3.6
5AM Ventures IV, L.P.
Large shareholder
333,333 +inf%
15.00
US$4,999,995 		333,333 +inf% 15.00 US$4,999,995
2019-10-08 2019-10-07 B Purchase
3.2
Redmile Group, LLC
Large shareholder
400,000 +21.4%
15.00
US$6,000,000 		400,000 +21.4% 15.00 US$6,000,000
2019-10-07 2019-10-07 B Purchase
Korbel Gregory Alan

VP of Business Dev't
500 +inf%
15.00
US$7,500 		500 +inf% 15.00 US$7,500
2019-10-07 2019-10-07 B Purchase
0.6
HealthCap VII, L.P.
Large shareholder
266,667 +12.7%
15.00
US$4,000,005 		266,667 +12.7% 15.00 US$4,000,005
2019-10-07 2019-10-07 B Purchase
Coiante Scott M

SVP, Chief Financial Officer
2,500 +inf%
15.00
US$37,500 		2,500 +inf% 15.00 US$37,500
2019-10-07 2019-10-07 B Purchase
Attar Eyal C.

SVP, Chief Medical Officer
200 +inf%
15.00
US$3,000 		200 +inf% 15.00 US$3,000
2019-10-07 2019-10-07 B Purchase
Attar Eyal C.

SVP, Chief Medical Officer
200 +inf%
15.00
US$3,000 		200 +inf% 15.00 US$3,000
2019-10-07 2019-10-07 B Purchase
3.4
HENNEMAN JOHN B III
5,000 +inf%
15.00
US$75,000 		5,000 +inf% 15.00 US$75,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
5,000 +inf%
15.00
US$75,000 		5,000 +inf% 15.00 US$75,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
1,000 +inf%
15.00
US$15,000 		1,000 +inf% 15.00 US$15,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
1,000 +inf%
15.00
US$15,000 		1,000 +inf% 15.00 US$15,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
1,000 +inf%
15.00
US$15,000 		1,000 +inf% 15.00 US$15,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
1,000 +inf%
15.00
US$15,000 		1,000 +inf% 15.00 US$15,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
1,000 +inf%
15.00
US$15,000 		1,000 +inf% 15.00 US$15,000
2019-10-07 2019-10-07 B Purchase
2.2
SCHADE CHRISTIAN S

President & CEO
1,000 +inf%
15.00
US$15,000 		1,000 +inf% 15.00 US$15,000
2019-10-07 2019-10-07 B Purchase
Versant V Luxco S.a r.l.
333,333 +inf%
15.00
US$4,999,995 		333,333 +inf% 15.00 US$4,999,995
2019-10-07 2019-10-07 B Purchase
0.6
Christenson Johan
266,667 +12.7%
15.00
US$4,000,005 		266,667 +12.7% 15.00 US$4,000,005
2019-10-07 2019-10-07 B Purchase
0.9
Versant Vantage I, L.P.
333,333 +inf%
15.00
US$4,999,995 		333,333 +inf% 15.00 US$4,999,995
2019-10-07 2019-10-07 B Purchase
Magni Guido
6,500 +inf%
15.00
US$97,500 		6,500 +inf% 15.00 US$97,500
Explore more

More insider trading research around Aprea Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America